
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics is experiencing positive momentum and progress with its clinical trials and commercialization of CNSide. The company is expected to hit key milestones in 2026, especially in regards to its treatments for CNS cancers like GBM and LM. However, there may be risk factors to consider and the company has a history of needing to conduct reverse stock splits, which could create volatility for investors. Overall, with a solid financial position and major contracts in place, the company has the potential for significant upside and growth in the long term.
Bears say
Plus Therapeutics is facing financial struggles, as evidenced by their Q1 2022 results, with only $15 million in cash and $1 million in debt, and recent Q4 results showing EPS of $(1.01). Additionally, While the acquisition of CNSide provides some potential commercial opportunities, the company will not fully ramp up its launch until Q4 of 2026. With limited cash and potential delays in commercialization, Plus Therapeutics will likely face continuing financial challenges, causing a negative outlook for their stock.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares